Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-center, single-blind, phase 1 dose-ranging study to assess fecal bile acid excretion by Volixibat and coadministration with Loperamide in healthy adults

Next Previous
Trial Profile

A single-center, single-blind, phase 1 dose-ranging study to assess fecal bile acid excretion by Volixibat and coadministration with Loperamide in healthy adults

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Volixibat (Primary) ; Loperamide
  • Indications Cholestasis; Intrahepatic cholestasis; Primary sclerosing cholangitis
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 14 Nov 2024 According to a Mirum Pharmaceuticals Media Release, company will present data from this trial at the American Association for the Study of Liver Disease's (AASLD) The Liver Meeting, taking place Nov 15-19, 2024, in San Diego, California.
  • 29 Jan 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top